Issues raised in clinical researches using anti-vascular endothelial growth factor drugs to treat choroidal neovascularization / 中华眼底病杂志

ABSTRACT

Anti-vascular endothelial growth factor (VEGF) drugs have become the first-line medications for the treatment of choroidal neovascularization (CNV).Its efficacy and safety have been confirmed by evidence-based medicine and a large number of clinical studies.However there are several issues need to be discussed before reaching a consensus for the clinical application of anti-VEGF drugs.These issues include,but not limited to the individual treatment regimen for different CNV lesions,the best anti-VEGF drug regimen,the indications and schemes of combination therapy,the factors affecting the efficacy,the potential risks of systemic and local deliveries.How to establish a reasonable personalized regimen of anti-VEGF drugs is the 1st issue need to be explored.Ranibizumab will come into China market soon.We need utilize the existing evidence-based medical research findings; take our advantages of rich resources of patients to investigate those issues to further promote the anti-VEGF applications in China.